Abstract The Australasian Psoriasis Collaboration has developed a clinical practice
narrative with respect to the relationship between psoriasis, its treatment and infection. The …

Psoriasis is a chronic inflammatory disease of the skin affecting approximately 2% of the
world's population. Systemic treatments, including methotrexate and cyclosporin, are …

Background Psoriasis patients carry an increased risk for associated comorbidities.
Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis …

1.1 Bedarfsanalyse/Probleme in der Versorgung der Patienten Die Psoriasis vulgaris stellt
eine häufige und fast immer chronisch verlaufende dermatologische Erkrankung dar. Die …

Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …

■ Abstract Tumor necrosis factor (TNF)-α has been identified as a key cytokine mediating
cutaneous inflammation in the pathogenesis of psoriasis. The TNF inhibitors (TNFi's) …

Psoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key
clinical symptoms, including itching, pain, and scaling. PsO is associated with a high …

Hepatitis B Virus (HBV) reactivation in patients receiving chemotherapy, biologicals,
immunosupressants, or corticosteroids is emerging to be an important cause of morbidity …

The cytokine storm from the evolution of severe cases of COVID‑19, requiring strong
immunosuppressive therapies, has raised the issue of reactivation of hepatitis B virus (HBV) …

AIM To evaluate the outcomes in biological treatment and quality of life of psoriatic patients
with chronic hepatitis C (CHC) treated with new Direct-Acting Antiviral agents (DAAs) …